Asad Haider

Eli Lilly And Co (NYSE:LLY) is scheduled to report its quarterly results on Thursday. The company is likely to report its first-quarter results in line with peers, with some tariff and policy-related commentary during the earnings call, according to Goldman Sachs. The Eli Lilly Analyst: Analyst...

Eli Lilly & Co. (NYSE:LLY) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple in size by 2030. The stock surged, closing the day up 14....

Johnson & Johnson (NYSE:JNJ) reported upbeat first-quarter results on Wednesday. Here are some key analyst takeaways. Goldman Sachs On Johnson & Johnson Analyst Asad Haider maintained a Buy rating and price target of $172. Despite Stelara sales declining due to the arrival of biosimilars in...

While the consensus seems to underappreciate the trajectory of Johnson & Johnson's (NYSE:JNJ) Innovative Medicine business, Goldman Sachs says concerns around the Stelara loss of exclusivity appear overdone. The Johnson & Johnson Analyst: Analyst Asad Haider upgraded the rating from Neutral...

After a year of sector underperformance, several factors are coalescing to make 2020 a better year for the health care sector, Goldman Sachs said Monday as it added three stocks to its conviction list. The Analyst Asad Haider added Amgen, Inc. (NASDAQ: AMGN), UnitedHealth Group Inc (NYSE: UNH...

Most healthcare stocks have had a rough election season this year after Hillary Clinton made prescription drug prices a centerpiece of her campaign. In fact, the Health Care SPDR (ETF) (NYSE: XLV) is down 3.2 percent thus far in 2016. Healthcare investors are bracing for some significant volatility...